Pancreatic Cancer Research

ResearcherGerman Cancer Research CenterActive in the last 2 years

Günter Schneider

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-1840-4508; OpenAlex author ID A5084866392. Sources: OpenAlex.

Their work

Papers
66 (first author 6, last author 18)
Trials
0
Grants
0
Labs led
2
Collaborators
180
Papers, trials and grants by year

2011: 4 papers · 2012: 1 paper · 2013: 2 papers · 2014: 3 papers · 2015: 1 paper · 2016: 5 papers · 2017: 3 papers · 2018: 4 papers · 2019: 2 papers · 2020: 5 papers · 2021: 6 papers · 2022: 8 papers · 2023: 3 papers · 2024: 6 papers · 2025: 5 papers · 2026: 8 papers

Papers 50 of 66

  1. The Protein Phosphatase Inhibitor LB100 Targets the Mesenchymal Lineage of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1002/mco2.70794↗
  2. Targeting Mutual Dependence of Phosphatidylinositol-3-Kinase α/δ and Small Ubiquitin-Like Modifier Signaling in Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2025.08.018↗
  3. GSK3βhigh/NFATc1high subtype targeting overcomes therapy resistance in pancreatic cancer through transcriptional induction of homologous recombination repair. Co-author DOI 10.1136/gutjnl-2025-336227↗
  4. Targeting PRMT5 Inhibitor-Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam. Last author DOI 10.1158/2767-9764.crc-25-0670↗
  5. Spatially-resolved subtype progression reveals metabolic vulnerabilities in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12943-026-02628-3↗
  6. Cross-species single-cell atlases chart progression, therapy-driven remodelling and immune evasion in pancreatic cancer Co-author DOI 10.64898/2026.03.19.712924↗
  7. Modeling pancreatic cancer tumor stroma co-evolution in an in ovo model Co-author DOI 10.64898/2026.06.26.734719↗
  8. Loss of the Y chromosome drives basal identity and metastatic potential via epigenetic reprogramming in pancreatic cancer Co-author DOI 10.64898/2026.10.06.756936↗
  9. KRAS G 12C-inhibitor-based combination therapies for pancreatic cancer: insights from drug screening. Last author DOI 10.1002/1878-0261.13725↗
  10. PRMT5 inhibitors: Therapeutic potential in pancreatic cancer. Last author DOI 10.1016/j.tranon.2025.102366↗
  11. Simultaneous targeting of KRAS and CDK4 synergistically induces durable growth arrest in pancreatic cancer cells. Co-author DOI 10.1038/s41419-025-08362-w↗
  12. Heterogeneity-driven phenotypic plasticity and treatment response in branched-organoid models of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41551-024-01273-9↗
  13. Label-free single-cell phenotyping to determine tumor cell heterogeneity in pancreatic cancer in real time. Co-author DOI 10.1172/jci.insight.169105↗
  14. A Novel AMPK Inhibitor Sensitizes Pancreatic Cancer Cells to Ferroptosis Induction. Last author DOI 10.1002/advs.202307695↗
  15. Identification of the unfolded protein response pathway as target for radiosensitization in pancreatic cancer. Co-author DOI 10.1016/j.radonc.2023.110059↗
  16. Stress granules-membraneless organelles as therapeutic targets in pancreatic cancer. First author DOI 10.1038/s44321-024-00040-2↗
  17. An NFATc1/SMAD3/cJUN Complex Restricted to SMAD4-Deficient Pancreatic Cancer Guides Rational Therapies. Co-author DOI 10.1053/j.gastro.2023.10.026↗
  18. Comparison of endoscopic ultrasound-guided fine-needle aspiration and fine-needle biopsy to generate pancreatic cancer organoids: Randomized trial. Co-author DOI 10.1055/a-2257-3171↗
  19. A Hypoxia-Epigenetics Axis Drives EMT in Pancreatic Cancer. First author DOI 10.1158/0008-5472.can-23-3578↗
  20. Epigenetic control of pancreatic cancer metastasis. Last author DOI 10.1007/s10555-023-10132-z↗
  21. NF-κB/RelA controlled A20 limits TRAIL-induced apoptosis in pancreatic cancer. Co-author DOI 10.1038/s41419-022-05535-9↗
  22. Context-Specific Determinants of the Immunosuppressive Tumor Microenvironment in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-22-0876↗
  23. Indirect targeting of MYC sensitizes pancreatic cancer cells to mechanistic target of rapamycin (mTOR) inhibition. Last author DOI 10.1002/cac2.12280↗
  24. AP1/Fra1 confers resistance to MAPK cascade inhibition in pancreatic cancer. Last author DOI 10.1007/s00018-022-04638-y↗
  25. Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironment. Co-author DOI 10.1038/s43018-021-00326-1↗
  26. NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancer. Co-author DOI 10.1073/pnas.2105691119↗
  27. HDAC2 Facilitates Pancreatic Cancer Metastasis. Last author DOI 10.1158/0008-5472.can-20-3209↗
  28. Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype. Last author DOI 10.1172/jci.insight.151353↗
  29. Identification of treatment-induced vulnerabilities in pancreatic cancer patients using functional model systems. Co-author DOI 10.15252/emmm.202114876↗
  30. Targeting STAT3 Signaling Facilitates Responsiveness of Pancreatic Cancer Cells to Chemoradiotherapy. Co-author DOI 10.3390/cancers14051301↗
  31. Impact of DNA repair and reactive oxygen species levels on radioresistance in pancreatic cancer. Co-author DOI 10.1016/j.radonc.2021.03.038↗
  32. The SUMO pathway in pancreatic cancer: insights and inhibition. Last author DOI 10.1038/s41416-020-01119-6↗
  33. Mesenchymal Plasticity Regulated by Prrx1 Drives Aggressive Pancreatic Cancer Biology. Co-author DOI 10.1053/j.gastro.2020.09.010↗
  34. New Insights Into Pancreatic Cancer: Notes from a Virtual Meeting. First author DOI 10.1053/j.gastro.2021.04.082↗
  35. Rationale for MYC imaging and targeting in pancreatic cancer. Co-author DOI 10.1186/s13550-021-00843-1↗
  36. Class 1 Histone Deacetylases and Ataxia-Telangiectasia Mutated Kinase Control the Survival of Murine Pancreatic Cancer Cells upon dNTP Depletion. Co-author DOI 10.3390/cells10102520↗
  37. Targeting the ubiquitin-proteasome system in a pancreatic cancer subtype with hyperactive MYC. Co-author DOI 10.1002/1878-0261.12835↗
  38. Radiosensitization by Kinase Inhibition Revealed by Phosphoproteomic Analysis of Pancreatic Cancer Cells. Co-author DOI 10.1074/mcp.ra120.002046↗
  39. SUMO pathway inhibition targets an aggressive pancreatic cancer subtype. Co-author DOI 10.1136/gutjnl-2018-317856↗
  40. Implementing cell-free DNA of pancreatic cancer patient-derived organoids for personalized oncology. Co-author DOI 10.1172/jci.insight.137809↗
  41. Blocking the road to de-differentiation: HNF1A/KDM6A complex safeguards epithelial integrity in pancreatic cancer. First author DOI 10.15252/embj.2020104759↗
  42. Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches. Co-author DOI 10.1186/s13014-019-1345-6↗
  43. NF-κB Dependent Chemokine Signaling in Pancreatic Cancer. Co-author DOI 10.3390/cancers11101445↗
  44. Regulation of Epithelial Plasticity Determines Metastatic Organotropism in Pancreatic Cancer. Co-author DOI 10.1016/j.devcel.2018.05.025↗
  45. MTOR inhibitor-based combination therapies for pancreatic cancer. Last author DOI 10.1038/bjc.2017.421↗
  46. Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes. Co-author DOI 10.1038/nature25459↗
  47. TRAIL/NF-κB/CX3CL1 Mediated Onco-Immuno Crosstalk Leading to TRAIL Resistance of Pancreatic Cancer Cell Lines. Co-author DOI 10.3390/ijms19061661↗
  48. Role of CCL20 mediated immune cell recruitment in NF-κB mediated TRAIL resistance of pancreatic cancer. Co-author DOI 10.1016/j.bbamcr.2017.02.005↗
  49. HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer. Last author DOI 10.1038/onc.2016.344↗
  50. The hepatic microenvironment essentially determines tumor cell dormancy and metastatic outgrowth of pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/2162402x.2017.1368603↗

Closest collaborators

The 25 strongest of 180 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Dieter Saur · 40 shared papers, 2011–2026 · strength 4.37
  2. Maximilian Reichert · 27 shared papers, 2013–2026 · strength 3.10
  3. Matthias Wirth · 23 shared papers, 2011–2026 · strength 2.91
  4. Carolin Schneider · 14 shared papers, 2022–2026 · strength 2.78
  5. Roland Rad · 22 shared papers, 2014–2026 · strength 2.55
  6. Roland Michael Schmid · 26 shared papers, 2011–2026 · strength 2.43
  7. Elisabeth Heßmann · 14 shared papers, 2016–2026 · strength 2.39
  8. Christian Schneeweis · 16 shared papers, 2018–2026 · strength 2.35
  9. Oliver Holger Krämer · 14 shared papers, 2011–2026 · strength 1.46
  10. Lukas Krauß · 9 shared papers, 2022–2026 · strength 1.42
  11. Felix Orben · 10 shared papers, 2020–2026 · strength 1.30
  12. Stefanie Bärthel · 7 shared papers, 2020–2026 · strength 1.25
  13. Volker Ellenrieder · 8 shared papers, 2016–2026 · strength 1.22
  14. Michael B. Ghadimi · 6 shared papers, 2024–2026 · strength 1.11
  15. Ulrich Bernd Keller · 7 shared papers, 2020–2026 · strength 1.06
  16. Zonera Hassan · 11 shared papers, 2017–2022 · strength 1.05
  17. Marian Grade · 6 shared papers, 2022–2026 · strength 0.99
  18. Constanza Tapia Contreras · 5 shared papers, 2024–2026 · strength 0.92
  19. Chiara Falcomatà · 6 shared papers, 2021–2026 · strength 0.88
  20. Lena‐Christin Conradi · 4 shared papers, 2025–2026 · strength 0.77
  21. Daniele Lucarelli · 4 shared papers, 2022–2026 · strength 0.71
  22. Alexander Arlt · 8 shared papers, 2014–2023 · strength 0.70
  23. Ulrich Sax · 4 shared papers, 2024–2026 · strength 0.70
  24. Bernhard Küster · 5 shared papers, 2020–2025 · strength 0.63
  25. Aristeidis Papargyriou · 5 shared papers, 2020–2025 · strength 0.63

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.